Stay updated with breaking news from Acticor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug
Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today
This patent protects the use of glenzocimab in thrombotic diseases until 2036 This patent has already been granted in the United States and Singapore and is in the process of being granted